Ikarian Capital’s OnKure Therapeutics OKUR Stock Holding History

Ikarian Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-253,754	Closed	-$1.09M	–	195
2025 Q1	$1.09M	Hold	253,754	–	–	0.13%	94
2024 Q4	$2.18M	Buy	253,754 +151,187	+147%	+$2.29M	0.3%	76
2024 Q3	$1.74M	Buy	+102,567	New	+$1.52M	0.24%	74
2024 Q1	–	Sell	-42,130	Closed	-$674K	–	182
2023 Q4	$674K	Buy	+42,130	New	+$2.63M	0.06%	109
2023 Q3	–	Sell	-15,582	Closed	-$1.02M	–	174
2023 Q2	$1.02M	Hold	15,582	–	–	0.16%	84
2023 Q1	$932K	Hold	15,582	–	–	0.21%	83
2022 Q4	$363K	Hold	15,582	–	–	0.09%	63
2022 Q3	$521K	Sell	15,582 -2,978	-16%	-$97.8K	0.1%	83
2022 Q2	$491K	Hold	18,560	–	–	0.09%	105
2022 Q1	$546K	Buy	18,560 +1,060	+6%	+$59.3K	0.07%	133
2021 Q4	$1.5M	Hold	17,500	–	–	0.22%	82
2021 Q3	$1.3M	Buy	+17,500	New	+$1.49M	0.09%	147

Other funds holding OKUR

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Ikarian Capital's OKUR Position: Q2 2025 in Review

Ikarian Capital sold out of OnKure Therapeutics (OKUR) in Q2 2025, closing a stake of 253,754 shares — an estimated $1.09M sold.

Ikarian Capital first reported a position in OKUR in Q3 2021 and held it in 12 quarters. The position peaked at $2.18M in Q4 2024. 49 funds tracked by Wall St. Rank hold OKUR as of Q2 2025.

Ikarian Capital reported no remaining OnKure Therapeutics position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 253,754 OnKure Therapeutics shares in Q2 2025, an estimated $1.09M.
Ikarian Capital first reported a position in OnKure Therapeutics in Q3 2021 and held it in 12 quarters.
Ikarian Capital's OnKure Therapeutics position peaked at $2.18M in Q4 2024.
49 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.